Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Century Therapeutics Inc (IPSC)

$2.26 +0.07 (3.20%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	393.59M
Revenue (ttm)	109.16M
Net Income (ttm)	-9.58M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-8.78%
Debt to Equity Ratio	0.00

Volume	1,573,300
Avg Vol	1,374,076
Day's Range	N/A - N/A
Shares Out	179.72M
Stochastic %K	67%
Beta	1.66
Analysts	Strong Sell
Price Target	$4.27

Company Profile

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 a...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 817 5790

Website: www.centurytx.com

Address:

25 North 38th Street, 11th Floor, Philadelphia, United States

Beanie_Mojo Apr. 8 at 11:53 AM

$IPSC 💥💥💥 this will rise beyond $3+ 💥💥💥. showings 7% 🔥 premarket 🔥

0 · Reply

ChicagoJoe20 Apr. 7 at 11:33 PM

$IPSC hello all. I've just learned of this tech.

0 · Reply

Beanie_Mojo Apr. 7 at 11:06 PM

$IPSC ▶️ $2.50 ... 🚗💨💨💨 next 🚏

0 · Reply

Beanie_Mojo Apr. 7 at 1:30 PM

$IPSC

0 · Reply

Beanie_Mojo Apr. 6 at 1:52 PM

$IPSC Climbing 🔝

0 · Reply

Beanie_Mojo Apr. 2 at 12:15 PM

$IPSC Getting there :::::::: 👀🔥

0 · Reply

Beanie_Mojo Apr. 1 at 3:59 PM

$IPSC 20c away from 2.50 💥💥

0 · Reply

Beanie_Mojo Apr. 1 at 10:54 AM

$IPSC slap towards :::::: $2.50 ::::: stay calm and see it in action 🍿

0 · Reply

Beanie_Mojo Apr. 1 at 1:46 AM

$IPSC 👀... lookin good !

0 · Reply

Beanie_Mojo Mar. 31 at 3:19 PM

$IPSC Fired off !!

0 · Reply

Century Therapeutics to Participate in Upcoming Investor Conferences in March

Feb 16, 2026, 1:00 PM EST - 7 weeks ago

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

FATE

Nov 25, 2025, 4:01 PM EST - 4 months ago

Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 7:30 AM EST - 5 months ago

Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 13, 2025, 7:00 AM EST - 5 months ago

Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes

Oct 14, 2025, 4:01 PM EDT - 6 months ago

Century Therapeutics to Present at Chardan's 9th Annual Genetic Medicines Conference

Aug 22, 2025, 8:00 AM EDT - 8 months ago

Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 4:01 PM EDT - 8 months ago

Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

May 28, 2025, 4:01 PM EDT - 11 months ago

Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress

May 15, 2025, 4:01 PM EDT - 11 months ago

Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Nov 26, 2024, 7:00 AM EST - 1 year ago

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 5, 2024, 9:05 AM EST - 1 year ago

Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 4, 2024, 7:00 AM EST - 1 year ago

Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Sep 26, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jun 3, 2024, 7:00 AM EDT - 2 years ago

Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting

May 9, 2024, 7:30 AM EDT - 2 years ago

Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Apr 23, 2024, 7:00 AM EDT - 2 years ago

Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Apr 11, 2024, 7:00 AM EDT - 2 years ago

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics

Apr 8, 2024, 4:05 PM EDT - 2 years ago

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 19, 2024, 7:00 AM EDT - 2 years ago

Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 14, 2024, 7:30 AM EDT - 2 years ago

Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

Mar 5, 2024, 6:03 PM EST - 2 years ago

Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Feb 1, 2024, 7:00 AM EST - 2 years ago

Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Dec 9, 2023, 12:00 PM EST - 2 years ago

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

Dec 6, 2023, 7:30 AM EST - 2 years ago

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

$Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus$